Why the bargain the GOP and President Trump may be unraveling and more questions about Trump family business entanglements here and abroad
Guest Host: Steve Roberts
Vioxx, antidepressants, and a new FDA drug safety board are all on the agenda as Steve Roberts leads a discussion about the Food and Drug Administration and how well it is protecting consumers.
- Marc Kaufman Reporter on the national desk of "The Washington Post"
- Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. Jerry Avorn Author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
Most Recent Shows
Reaction to this week's political shocks, why many conservatives are choosing to double down on Trump critics, and then, a conversation on the growing dis-union in America.
Political fallout from the dismissal of FBI director James Comey, how our government created racially segregated cities, and a young Palestinian's perspective on Mideast peace.
Washington Post reporter Dan Balz on covering President Trump and linguist Deborah Tannen on how women support each other with the words they use.